JPH07508711A - Cd28経路免疫調節 - Google Patents
Cd28経路免疫調節Info
- Publication number
- JPH07508711A JPH07508711A JP5517745A JP51774593A JPH07508711A JP H07508711 A JPH07508711 A JP H07508711A JP 5517745 A JP5517745 A JP 5517745A JP 51774593 A JP51774593 A JP 51774593A JP H07508711 A JPH07508711 A JP H07508711A
- Authority
- JP
- Japan
- Prior art keywords
- ligand
- cells
- receptor
- cell
- stimulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 title claims description 174
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 title claims description 174
- 230000037361 pathway Effects 0.000 title claims description 37
- 230000002519 immonomodulatory effect Effects 0.000 title description 5
- 210000004027 cell Anatomy 0.000 claims description 289
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 273
- 239000003446 ligand Substances 0.000 claims description 146
- 238000000034 method Methods 0.000 claims description 136
- 230000000638 stimulation Effects 0.000 claims description 126
- 238000004519 manufacturing process Methods 0.000 claims description 95
- 102000005962 receptors Human genes 0.000 claims description 86
- 108020003175 receptors Proteins 0.000 claims description 86
- 108010002350 Interleukin-2 Proteins 0.000 claims description 76
- 230000004913 activation Effects 0.000 claims description 67
- 230000001965 increasing effect Effects 0.000 claims description 65
- 230000004936 stimulating effect Effects 0.000 claims description 59
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 55
- 239000000427 antigen Substances 0.000 claims description 55
- 108091007433 antigens Proteins 0.000 claims description 54
- 102000036639 antigens Human genes 0.000 claims description 54
- 238000006366 phosphorylation reaction Methods 0.000 claims description 53
- 230000026731 phosphorylation Effects 0.000 claims description 52
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 48
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 48
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 45
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 42
- 102000008072 Lymphokines Human genes 0.000 claims description 38
- 108010074338 Lymphokines Proteins 0.000 claims description 38
- 238000011282 treatment Methods 0.000 claims description 36
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 35
- 230000004044 response Effects 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 32
- 230000001404 mediated effect Effects 0.000 claims description 30
- 238000001727 in vivo Methods 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 230000028993 immune response Effects 0.000 claims description 20
- 230000001413 cellular effect Effects 0.000 claims description 19
- 230000006698 induction Effects 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 15
- 210000001185 bone marrow Anatomy 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 230000019491 signal transduction Effects 0.000 claims description 12
- 230000003213 activating effect Effects 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 206010011968 Decreased immune responsiveness Diseases 0.000 claims description 5
- 239000002299 complementary DNA Substances 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 4
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 4
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 claims description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 230000024932 T cell mediated immunity Effects 0.000 claims description 2
- 244000045947 parasite Species 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000003915 cell function Effects 0.000 claims 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 206010011732 Cyst Diseases 0.000 claims 1
- VJBCNMFKFZIXHC-UHFFFAOYSA-N azanium;2-(4-methyl-5-oxo-4-propan-2-yl-1h-imidazol-2-yl)quinoline-3-carboxylate Chemical compound N.N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O VJBCNMFKFZIXHC-UHFFFAOYSA-N 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 108091008042 inhibitory receptors Proteins 0.000 claims 1
- 244000145841 kine Species 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 229930014626 natural product Natural products 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 description 75
- 230000014509 gene expression Effects 0.000 description 69
- 230000000694 effects Effects 0.000 description 58
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 57
- 241001465754 Metazoa Species 0.000 description 55
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 42
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 42
- 230000035755 proliferation Effects 0.000 description 41
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 34
- 108010036949 Cyclosporine Proteins 0.000 description 34
- 108091008874 T cell receptors Proteins 0.000 description 32
- 230000003013 cytotoxicity Effects 0.000 description 30
- 231100000135 cytotoxicity Toxicity 0.000 description 30
- 229960001265 ciclosporin Drugs 0.000 description 29
- 229930182912 cyclosporin Natural products 0.000 description 27
- 238000002474 experimental method Methods 0.000 description 27
- 210000004698 lymphocyte Anatomy 0.000 description 27
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 26
- 238000000338 in vitro Methods 0.000 description 26
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 26
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 26
- 230000006052 T cell proliferation Effects 0.000 description 23
- 238000009169 immunotherapy Methods 0.000 description 23
- 102100040247 Tumor necrosis factor Human genes 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 22
- 238000010322 bone marrow transplantation Methods 0.000 description 22
- 239000002609 medium Substances 0.000 description 22
- 230000006870 function Effects 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 21
- 239000000523 sample Substances 0.000 description 20
- 230000009696 proliferative response Effects 0.000 description 19
- 230000006044 T cell activation Effects 0.000 description 18
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 18
- 230000000284 resting effect Effects 0.000 description 18
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 16
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 16
- 239000006228 supernatant Substances 0.000 description 16
- 108010002386 Interleukin-3 Proteins 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 14
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 14
- 102100039064 Interleukin-3 Human genes 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 14
- 210000005266 circulating tumour cell Anatomy 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 230000000735 allogeneic effect Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 238000004132 cross linking Methods 0.000 description 12
- 231100000655 enterotoxin Toxicity 0.000 description 12
- 230000028327 secretion Effects 0.000 description 12
- 229930105110 Cyclosporin A Natural products 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 230000030833 cell death Effects 0.000 description 11
- 230000021633 leukocyte mediated immunity Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 108090000978 Interleukin-4 Proteins 0.000 description 10
- 102000004388 Interleukin-4 Human genes 0.000 description 10
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 10
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 10
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 229940104230 thymidine Drugs 0.000 description 10
- 108010047620 Phytohemagglutinins Proteins 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 239000000147 enterotoxin Substances 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- 210000005087 mononuclear cell Anatomy 0.000 description 9
- 101710146739 Enterotoxin Proteins 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 8
- 230000000139 costimulatory effect Effects 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 230000001506 immunosuppresive effect Effects 0.000 description 8
- 101150113162 pbl gene Proteins 0.000 description 8
- 230000001885 phytohemagglutinin Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 210000001541 thymus gland Anatomy 0.000 description 8
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 7
- 101100313161 Caenorhabditis elegans mab-9 gene Proteins 0.000 description 7
- 206010062016 Immunosuppression Diseases 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000022131 cell cycle Effects 0.000 description 7
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 7
- 238000010348 incorporation Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 229910052698 phosphorus Inorganic materials 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- -1 IIcMV Chemical compound 0.000 description 6
- 108010002616 Interleukin-5 Proteins 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 238000000636 Northern blotting Methods 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 230000003828 downregulation Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000003226 mitogen Substances 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 231100000617 superantigen Toxicity 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 5
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 206010052779 Transplant rejections Diseases 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 230000004940 costimulation Effects 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 5
- 229940045145 uridine Drugs 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 4
- 241000257465 Echinoidea Species 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 239000012979 RPMI medium Substances 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 230000000961 alloantigen Effects 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 210000004970 cd4 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 4
- 230000017306 interleukin-6 production Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 239000006249 magnetic particle Substances 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000004043 responsiveness Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 240000006365 Vitis vinifera Species 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000007402 cytotoxic response Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000004073 interleukin-2 production Effects 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920000379 polypropylene carbonate Polymers 0.000 description 3
- 238000002300 pressure perturbation calorimetry Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000005522 programmed cell death Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 102100032768 Complement receptor type 2 Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 2
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 101150085390 RPM1 gene Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 2
- 229960004484 carbachol Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000009743 cell cycle entry Effects 0.000 description 2
- 230000006369 cell cycle progression Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 210000004754 hybrid cell Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000011694 lewis rat Methods 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 231100000004 severe toxicity Toxicity 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 101100408068 Amanita phalloides PHA1 gene Proteins 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000642258 Homo sapiens Spondin-2 Proteins 0.000 description 1
- 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 241000408495 Iton Species 0.000 description 1
- 241000102542 Kara Species 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 206010025280 Lymphocytosis Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- DMUAPQTXSSNEDD-QALJCMCCSA-N Midecamycin Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C DMUAPQTXSSNEDD-QALJCMCCSA-N 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241001553014 Myrsine salicina Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 101150111781 PGL1 gene Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 235000012012 Paullinia yoco Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241001377010 Pila Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 102100036427 Spondin-2 Human genes 0.000 description 1
- 230000010782 T cell mediated cytotoxicity Effects 0.000 description 1
- 230000006043 T cell recruitment Effects 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 101150071577 chi2 gene Proteins 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 201000010549 croup Diseases 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001454 enterotrophic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000046157 human CSF2 Human genes 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000018276 interleukin-1 production Effects 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229920000554 ionomer Polymers 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229960002757 midecamycin Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
- 230000012177 negative regulation of immune response Effects 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940046781 other immunosuppressants in atc Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000007414 peripheral immune response Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- ZDWVWKDAWBGPDN-UHFFFAOYSA-O propidium Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 ZDWVWKDAWBGPDN-UHFFFAOYSA-O 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 101150022630 prp5 gene Proteins 0.000 description 1
- 208000015476 pseudohypoaldosteronism type 1 Diseases 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000020837 signal transduction in absence of ligand Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
Abstract
Description
Claims (111)
- 1.T細胞群を有する受容者が、インビボにおいて抗原にさらされて感作され、 ここで該受容者のT細胞群の少なくとも一部が該抗原によって活性化されている 、該抗原に対するT細胞介在性応答を選択的に増強する方法であって、以下の工 程: a)CD28レセプターの細胞外ドメインに結合し得る、CD28刺激リガンド を選択する工程;b)該リガンドを、インビボでの投与に適切な生物学的に連合 し得る形態で提供する工程;およびc)該提供されたリガンドを、該活性化され たT細胞によりTmCD28リンホカイン平均細胞産生を増加させるのに充分な 量で、該受容者に投与する工程; を包含する、方法。
- 2.前記刺激リガンドが、実質的に、抗CD28抗体およびその刺激フラグメン ト、天然のCD28リガンドおよびその刺激相同物、および、それらの有効な組 み合わせからなる群から選択される、請求項1に記載の方法。
- 3.前記リガンドが抗CD28抗体を包含する、請求項1に記載の方法。
- 4.前記リガンドがCD28レセプターに対する天然のリガンドを包含する、請 求項1に記載の方法。
- 5.前記リガンドが合成物由来である、請求項1に記載の方法。
- 6.前記リガンドが組換え分子を包含する、請求項1に記載の方法。
- 7.前記リガンドが天然のリガンドの刺激相同物である、請求項2に記載の方法 。
- 8.前記抗体が、モノクローナル抗体を包含する、請求項3に記載の方法。
- 9.前記リガンドがF(ab′)■フラグメントを包含する、請求項3に記載の 方法。
- 10.前記モノクローナル抗体がmAb9.3を包含する、請求項3に記載の方 法。
- 11.CD28+T細胞群を有する受容者に投与され、それにより該T細胞群の 少なくとも一部を活性化する外来の抗原に対する、インビボでのT細胞介在免疫 応答を上昇させる方法であって、以下の工程: a)CD28レセプターの細胞外ドメインに結合し得る、CD28刺激リガンド を選択する工程;b)該リガンドを、インビボでの投与に適切な生物学的に適合 し得る形態で提供する工程;およびc)該提供されたリガンドを、該CD28レ セプターへの結合およびその刺激に充分な量で、該受容者に投与する工程; を包含する、方法:: ここで、該免疫応答の上昇は、該活性化されたT細胞によるTmCD28リンホ カイン平均細胞産生の増大を包含する。
- 12.前記刺激リガンドが、実質的に、抗CD28抗体およびその刺激フラグメ ント、天然のCD28リガンドおよびその刺激相同物、および、それらの有効な 組み合わせからなる郡から選択される、請求項11に記載の方法。
- 13.前記リガンドが抗CD28抗体を包含する、請求項11に記載の方法。
- 14.前記リガンドがCD28レセプターに対する天然のリガンドを包含する、 請求項11に記載の方法。
- 15.前記リガンドが合成物由来である、請求項11に記載の方法。
- 16.前記リガンドが組換え分子を包含する、請求項11に記載の方法。
- 17.前記リガンドが天然のリガンドの刺激相同物である、請求項12に記載の 方法。
- 18.前記抗体が、モノクローナル抗体を包含する、請求項13に記載の方法。
- 19.前記リガンドがF(ab′)■フラグメントを包含する、請求項13に記 載の方法。
- 20.前記モノクローナル抗体がmAb9.3を包含する、請求項13に記載の 方法。
- 21.T細胞群を有する受容者での、選択された外来の抗原に対する免疫応答の 増強を誘導する方法であって、以下の工程: a)該外来の抗原を、該T細胞群の一部を活性化するのに充分な量で、該受容者 に投与する工程;b)CD28レセプターに対して特異的な、選択された刺激リ ガンドを、インビボでの投与に適切な生物学的に適合し得る形態で提供する工程 ;および c)該選択されたリガンドを、該CD28レセプターを刺激するのに充分な量で 投与する工程; を包含する、方法。
- 22.前記リガンドが抗CD28抗体を包含する、請求項21に記載の方法。
- 23.前記リガンドがCD28に対する天然のリガンドを包含する、請求項21 に記載の方法。
- 24.前記リガンドが組換え分子を包含する、請求項21に記載の方法。
- 25.前記リガンドが合成物由来である、請求項21に記載の方法。
- 26.前記外来の抗原が微生物抗原を包含する、請求項21に記載の方法。
- 27.前記抗原が寄生体抗原を包含する、請求項21に記載の方法。
- 28.前記抗原が、前記受容者内での抗原産生のために、該受容者に抗原cDN Aを提供することにより投与きれる、請求項21に記載の方法。
- 29.前記外来の抗原が細菌抗原を包含する、請求項26に記載の方法。
- 30.前記外来の抗原がウイルス抗原を包含する、請求項26に記載の方法。
- 31.前記外来の抗原が天然物由来である、請求項26に記載の方法。
- 32.前記抗原が合成物由来である、請求項26に記載の方法。
- 33.前記抗原が組換え分子を包含する、請求項26に記載の方法。
- 34.細胞のTmCD28リンホカイン産生を増大するのに効果的な量のCD2 8レセプター刺激リガンドと組み合わせて外来の抗原を含む、ワクチン。
- 35.TCR/CD3レセプターを活性化するのに効果的な量のTCR/CD3 レセプター刺激リガンドをさらに含む、請求項34に記載のワクチン。
- 36.T細胞抗原レセプターを介して刺激された無活動T細胞群のアネルギー誘 導を防止する方法であって、以下の工程: a)CD28レセプターの細胞外ドメインに結合し得る、CD28刺激リガンド を選択する工程;b)該リガンドを、生物学的に適合し得る形態で提供する工程 ;および c)該提供されたリガンドを、該CD28レセプターへの結合およびその刺激に 充分な量で、該細胞群に投与する工程を包含する、方法。
- 37.前記刺激リガンドが、実質的に、抗CD28抗体およびその刺激フラグメ ント、天然のCD28リガンドお上びその刺激相同物、および、それらの有効な 組み合わせからなる群から選択される、請求項36に記載の方法。
- 38.前記リガンドが抗CD28モノクローナル抗体を包含する、請求項36に 記載の方法。
- 39.前記リガンドが前記CD28レセプターに対する天然のリガンドを包含す る、請求項36に記載の方法。
- 40.前記リガンドが合成物由来である、請求項36に記載の方法。
- 41.前記リガンドが組換え分子を包含する、請求項36に記載の方法。
- 42.前記リガンドがF(ab′)■を包含する、請求項38に記載の方法。
- 43.前記抗体がmAb9.3を包含する、請求項38に記載の方法。
- 44.T細胞群における、TmCD28リンホカインの細胞産生の増大に関連す るCD28経路の活性化を阻害する方法であって、以下の工程: a)CD28レセプターの細胞外ドメインに結合し得るが、刺激し得ない阻害リ ガンドを選択する工程;b)該リガンドを、生物学的に適合し得る形態で提供す る工程;および c)該提供されたリガンドを、該CD28経路の活性化を阻害するのに充分な量 で、該T細胞群に投与する工程;を包含する、方法。
- 45.前記リガンドが前記CD28レセプターと架橋しない、請求項44に記載 の方法。
- 46.前記リガンドが改変された天然のリガンドを包含する、請求項44に記載 の方法。
- 47.前記リガンドが合成物由来である、請求項44に記載の方法。
- 48.前記リガンドが組換え分子を包含する、請求項44に記載の方法。
- 49.前記リガンドがF(8b′)を包含する、請求項44に記載の方法。
- 50.以下の工程: d)CD28天然リガンドに結合し得る第二の阻害リガンドを投与する工程; をさらに包含する、請求項44に記載の方法。
- 51.前記F(ab′)がmAb9.3のF(ab′)を包含する、請求項45 に記載の方法。
- 52.T細胞群におけるTmCD28リンホカインの細胞産生の増大に関連する 、CD28レセプター刺激結合部位に結合し得る第一の刺激リガンドによる、C D28経路の活性化を阻害する方法であって、以下の工程:a)CD28刺激リ ガンドに1結合し得る第二のリガンドを選択する工程; b)該第二のリガンドを、生物学的に適合し得る形態で提供する工程;および c)該提供された第二のリガンドを、競合的に結合し、そして該刺激リガンドの 該CD28レセプター刺激結合部位への結合を阻害するのに充分な量で投与する 工程;を包含する、方法。
- 53.前記刺激リガンドが天然のCD28リガンドを包含する、請求項52に記 載の方法。
- 54.前記第二のリガンドが前記刺激リガンドに対する抗体またはそのフラグメ ントを包含する、請求項52に記載の方法。
- 55.前記第二のリガンドが合成物由来である、請求項52に記載の方法。
- 56.前記第二のリガンドが組換え分子を包含する、請求項52に記載の方法。
- 57.以下の工程: d)前記CD28レセプターに結合し得るが刺激し得ない、第三のCD28レセ プター阻害リガンドを投与する工程;をさらに包含する、請求項52に記載の方 法。
- 58.前記投与がインビボにおいてなされる、請求項53に記載の方法。
- 59.前記第二のリガンドが、CD28またはCTLA−4の可溶性形態を包含 する、請求項52に記載の方法。
- 60.活性化されたT細胞群によるTmCD28リンホカインの細胞産生を抑制 する方法であって、以下の工程:a)CD28シグナル伝達経路に関連するチロ シンリン酸化のインヒビターを選択する工程; b)該インヒビターを、生物学的に適合し得る形態で提供する工程;および c)該提供されたインヒビターを、該チロシンリン酸化を阻害するのに充分な量 で投与する工程;を包含する、方法。
- 61.前記インヒビターがチロシンキナーゼのインヒビターを包含する、請求項 60に記載の方法。
- 62.前記インヒビターが細胞のホスファターゼを包含する、請求項60に記載 の方法。
- 63.前記インヒビターがハルビマイシンを包含する、請求項61に記載の方法 。
- 64.前記インヒビターがチロシンホスファターゼを包含する、請求項62に記 載の方法。
- 65.T細胞群によるTmCD28リンホカインの内因性の細飽産生の増強によ る、細胞傷害性T細胞機能を増大する方法であって、以下の工程: a)T細胞群を活性化する工程;およびb)CD28特異リガンドでCD28レ セプターを刺激する工程; を包含する、方法: ここで、該活性化および刺激の程度は、TmCD28リンホカインの内因性の細 胞産生を増大きせるのに充分な程度である。
- 66.前記活性化工程が、前記T細胞群を活性化するのに充分な量のTCR/C D3レセプターリガンドで、該細胞群を処理する工程をさらに包含する、請求項 65に記載の方法。
- 67.前記TCR/CD3レセプターリガンドが抗CD3抗体またはそのフラグ メントを包含する、請求項66に記載の方法。
- 68.前記CD28特異リガンドが、実質的に、抗CD28抗体およびその刺激 フラグメント、天然のCD28リガンドおよびその刺激相同物、および、それら の有効な組み合わせからなる群から選択される、請求項65に記載の方法。
- 69.前記CD28特異リガンドが抗CD28抗体を包含する、請求項66に記 載の方法。
- 70.前記CD28特異リガンドが、CD28レセプターに対する天然のリガン ドを包含する、請求項65に記載の方法。
- 71.前記CD28特異リガンドが合成物由来である、請求項65に記載の方法 。
- 72.前記CD28特異リガンドが組換え分子を包含する、請求項65に記載の 方法。
- 73.前記CD28特異リガンドが、天然のCD28特異リガンドの刺激相同物 である、請求項68に記載の方法。
- 74.前記抗体が、モノクローナル抗体を包含する、請求項69に記載の方法。
- 75.前記リガンドがF(ab′)■フラグメントを包含する、請求項69に記 載の方法。
- 76.前記モノクローナル抗体がmAb9.3を包含する、請求項74に記載の 方法。
- 77.前記TCR/CD3レセプターリガンドが、TCR/CD3に対する天然 のリガンドを包含する、請求項66に記載の方法。
- 78.前記抗CD3抗体がOKT3を包含する、請求項67に記載の方法。
- 79.前記TCR/CD3レセプターリガンドが合成物由来である、請求項66 に記載の方法。
- 80.前記TCR/CD3レセプターリガンドが組換え分子を包含する、請求項 66に記載の方法。
- 81.以下の工程: c)前記T細胞群を活性化前に受容者から除去する工程;および d)該細胞群を刺激後に該受容者に再導入する工程;をさらに包含する、請求項 65に記載の方法。
- 82.以下の工程: c)前記T細胞群を刺激前に受容者から除去する工程;および d)該細胞群を刺激後に該受容者に再導入する工程;をさらに包含する、請求項 65に記載の方法。
- 83.以下の工程: c)前記T細胞群を活性化および刺激前に受容者から除去する工程;および d)該細胞群を活性化および刺激後に該受容者に再導入する工程; をさらに包含する、請求項65に記載の方法。
- 84.前記活性化工程および刺激工程が、インビボにおけるT細胞群に対して行 われる、請求項65に記載の方法。
- 85.免疫学的に近接な個体のT細胞群により、TmCD28リンホカインの内 因性の細胞産生を場大させる方法であって、以下の工程: a)該細胞群の少なくとも一部を活性化するのに充分な量のTCR/CD3刺激 りガンドで、該細胞群を処理する工程;および b)該活性化されたT細脂群の少なくとも一部を刺激するのに充分な量のCD2 8刺激リガンドで、該細胞群を処理する工程; を包含する、方法。
- 86.以下の工程: c)TCR/CD3活性化およびCD28刺激前に、受容者から前記T細胞群を 除去する工程;およびd)TCR/CD3活性化およびCD28刺激後に、該該 受容者に、該T細胞群を再導入する工程;をさらに包含する、請求項85に記載 の方法。
- 87.前記TCR/CD3およびCD28レセプターリガンドによる処理が、同 時に実行される、請求項85に記載の方法。
- 88.前記丁mCD28リンホカインがIL−2を包含する、請求項85に記載 の方法。
- 89.前記TCR/CD3リガンドが、抗CD3抗体またはそのF(8b′)2 を包含する、請求項86に記載の方法。
- 90.前記CD28リガンドが、抗CD28抗体またはそのF(ab′)2を包 含する、請求項86に記載の方法。
- 91.前記CD28リガンドが、天然のCD28リガンドを包含する、請求項8 6に記載の方法。
- 92.前記CD28リガンドが、天然のCD28リガンドの刺激相同物を包含す る、請求項86に記載の方法。
- 93.前記CD28リガンドが合成物由来である、請求項86に記載の方法。
- 94.前記CD28リガンドが組換え分子を包含する、請求項86に記載の方法 。
- 95.骨髄移植受容者における、TmCD28リンホカインの細胞産生を増大す る方法であって、以下の工程:a)該受容者からT細胞群を除去する工程;b) 該除去された細胞群の少なくとも一部を活性化するのに充分な重のTCR/CD aレセプター刺激リガンドで、該除去された細胞群を処理する工程; c)CD28レセプターを刺激するのに充分な量のCD28レセプター刺激リガ ンドで、該除去された細胞群を処理する工程;および d)該受容者に、該処理された細胞群の少なくとも一部を再導入する工程; を包含する、方法。
- 96.前記TCR/CD3レセプターリガンドが、抗CD3抗体またはそのフラ グメントを包含する、請求項95に記載の方法。
- 97.前記CD28レセプターリガンドが、抗CD28抗体またはそのフラグメ ントを包含する、請求項95に記載の方法。
- 98.前記抗CD3抗体が、OKT3またはそのF(ab′)2を包含する、請 求項96に記載の方法。
- 99.前記抗CD28抗体が、mAb9.3またはそのF(ab′)2を包含す る、請求項97に記載の方法。
- 100.前記TCR/CD3レセプターリガンドが天然のリガンドを包含する、 請求項95に記載の方法。
- 101.前記CD28レセプターリガンドが天然のリガンドを包含する、請求項 95に記載の方法。
- 102.T細胞群を有する受容者が、インビボにおいて抗原にさらされて感作さ れ、ここで該受容者のT細胞群の少なくとも一部が該抗原によって活性化されて いる、該抗原に対するT細胞介在性応答を選択的に増強するための薬剤の製造に おける、CD28の油脂外ドメインに結合し得るCD28刺激リガンドの使用。
- 103.CD28+T細胞群を有する受容者に投与され、それにより該T細胞群 の少なくとも一部を活性化する外来の抗原に対する、インビボでのT細胞介在性 免疫応答を上昇させるための薬剤の製造における、CD28レセプターの細胞外 ドメインに結合し得るCD28刺激リガンドの使用:ここで、該免疫応答の上昇 は、該活性化されたT細胞によるTmCD28リンホカイン平均細胞産生の増大 を包含する。
- 104.T細胞群を有する受容者に対して選択された外来の抗原であって、該T 細胞群の少なくとも一部を活性化するのに充分な量で投与される外来の抗原に対 する、免疫応答の増強を誘導するための薬剤の製造における、CD28レセプタ ーに特異的な、選択された刺激リガンドの使用。
- 105.T細胞抗原レセプターを介して刺激される無活動T細胞群のアネルギー 誘導を防止するための薬剤の製造における、CD28レセプターの細胞外ドメイ ンに結合し得るCD28刺激リガンドの使用。
- 106.T細胞群における、TmCD28リンホカインの細胞産生の増大に関連 するCD28経路の活性化を阻害するための薬剤の製造における、CD28レセ プターの細胞外ドメインに結合し得るが、刺激し得ない阻害リガンドの使用。
- 107.T細胞群におけるTmCD28リンホカインの細胞産生の増大に関連す る、CD28レセプター刺激結合部位に結合し得る第一の刺激リガンドによる、 CD28経路の活性化を阻害するための薬剤の製造における、CD28刺激リガ ンドに競合的に結合し得、該刺激リガンドの該CD28レセプター刺激結合部位 への結合を阻害する、第二のリガンドの使用。
- 108.活性化されたt細胞群によるTmCD28リンホカインの細胞産生を抑 制するための薬剤の製造における、CD28シグナル伝達経路に関連するチロシ ンリン酸化のインヒビターの使用。
- 109.活性化されたT細胞群によるTmCD28リンホカインの内因性の細胞 産生の増強による、細胞傷害性T細胞機能を増大するための薬剤の製造における 、CD28レセプターを刺激するCD28特異リガンドの使用。
- 110.免疫学的に近接な個体の活性化されたT細胞群による、TmCD28リ ンホカインの内因性の細胞産生を増大させるための薬剤の製造における、該細胞 群の少なくとも一部を活性化するためのTCR/CD3刺激りかンド、該活性化 されたT細胞群の少なくとも一部を刺激するためのCD28刺激リガンド、また はそれらの両方、の使用。
- 111.骨髄移植受容者から除去され、薬剤による処理後に該受容者に再導入さ れたT細胞群でのTmCD28リンホカインの細胞産生を増大するための該薬剤 の製造における、該細胞群の少なくとも一部を活性化するためのTCR/CD3 レセプター刺激リガンド、CD28レセプターを刺激するためのCD28レセプ ター刺激リガンド、またはそれらの両方、の使用。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86480592A | 1992-04-07 | 1992-04-07 | |
US86486692A | 1992-04-07 | 1992-04-07 | |
US86480792A | 1992-04-07 | 1992-04-07 | |
US864,866 | 1992-04-07 | ||
US864,807 | 1992-04-07 | ||
US864,805 | 1992-04-07 | ||
US90246792A | 1992-06-19 | 1992-06-19 | |
US902,467 | 1992-06-19 | ||
PCT/US1993/003155 WO1993019767A1 (en) | 1992-04-07 | 1993-04-06 | Cd28 pathway immunoregulation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006284411A Division JP2007056034A (ja) | 1992-04-07 | 2006-10-18 | Cd28経路免疫調節 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH07508711A true JPH07508711A (ja) | 1995-09-28 |
Family
ID=27505942
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5517745A Ceased JPH07508711A (ja) | 1992-04-07 | 1993-04-06 | Cd28経路免疫調節 |
JP2006284411A Withdrawn JP2007056034A (ja) | 1992-04-07 | 2006-10-18 | Cd28経路免疫調節 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006284411A Withdrawn JP2007056034A (ja) | 1992-04-07 | 2006-10-18 | Cd28経路免疫調節 |
Country Status (7)
Country | Link |
---|---|
EP (2) | EP0637963B1 (ja) |
JP (2) | JPH07508711A (ja) |
AT (1) | ATE272708T1 (ja) |
AU (1) | AU684461B2 (ja) |
CA (1) | CA2133075A1 (ja) |
DE (1) | DE69333580D1 (ja) |
WO (1) | WO1993019767A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007056038A (ja) * | 1994-04-29 | 2007-03-08 | Usa Government | 細胞内シグナル変換操作によるt細胞応答の調節方法 |
JP2007056034A (ja) * | 1992-04-07 | 2007-03-08 | Regents Of The Univ Of Michigan | Cd28経路免疫調節 |
JP2007525225A (ja) * | 2004-02-26 | 2007-09-06 | イミュノバティブ セラピーズ, リミテッド | 細胞治療のためのt細胞を調製するための方法 |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7479269B2 (en) | 1988-11-23 | 2009-01-20 | Genetics Institute, Llc | Methods for selectively enriching TH1 and TH2 cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
DE69032484T4 (de) * | 1989-10-27 | 1999-09-16 | Arch Dev Corp | Zusammensetzungen und deren verwendung zur förderung der immunopotentiation |
US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
ATE293686T1 (de) * | 1993-06-04 | 2005-05-15 | Us Navy | Verfahren zur selektiven stimulierung der t- zellproliferation. |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US6719972B1 (en) | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
GB9607711D0 (en) * | 1996-04-13 | 1996-06-19 | Univ Sheffield | T-cell dependent vaccine |
CA2194814A1 (en) | 1997-01-10 | 1998-07-10 | Terry L. Delovitch | Stimulation of protective t cells to prevent autoimmune disease |
AU1395499A (en) * | 1997-11-10 | 1999-05-31 | Arch Development Corporation | Methods for treatment of tumors and tumor cells using (ex vivo) activated t cells |
US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
TWI322153B (en) | 2000-07-03 | 2010-03-21 | Bristol Myers Squibb Co | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
PL204899B1 (pl) | 2001-05-23 | 2010-02-26 | Bristol Myers Squibb Co | Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4 |
US20050084967A1 (en) | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
WO2004058800A2 (en) | 2002-12-23 | 2004-07-15 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
ES2354610T5 (es) | 2002-12-23 | 2020-09-14 | Bristol Myers Squibb Co | Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína |
BRPI0413326A (pt) | 2003-08-04 | 2006-10-10 | Bristol Myers Squibb Co | métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel |
SG10201504917PA (en) | 2005-07-11 | 2015-07-30 | Macrogenics Inc | Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity |
EP2037961B1 (en) | 2006-06-14 | 2015-11-11 | MacroGenics, Inc. | Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity |
EP2612868B1 (en) | 2007-11-01 | 2018-08-15 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
NZ587051A (en) | 2008-01-04 | 2012-12-21 | Intellikine Llc | Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase) |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
ES2593256T3 (es) | 2010-05-21 | 2016-12-07 | Infinity Pharmaceuticals, Inc. | Compuestos químicos, composiciones y métodos para las modulaciones de cinasas |
WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN103648499B (zh) | 2011-01-10 | 2017-02-15 | 无限药品股份有限公司 | 用于制备异喹啉酮的方法及异喹啉酮的固体形式 |
EP2734520B1 (en) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
WO2013032591A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
CA2925944C (en) | 2013-10-04 | 2023-01-10 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP4066834A1 (en) | 2014-03-19 | 2022-10-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP3239289B1 (en) * | 2014-12-25 | 2023-04-12 | Toyo Seikan Group Holdings, Ltd. | Culture container and method for manufacturing culture container |
CN108349985A (zh) | 2015-09-14 | 2018-07-31 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2017223422A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
GB201616238D0 (en) | 2016-09-23 | 2016-11-09 | Adaptimmune Ltd | Modified T cells |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2003455C (en) * | 1988-11-23 | 2000-02-22 | Craig B. Thompson | Immunotherapy involving cd28 stimulation |
ZA91463B (en) * | 1990-01-25 | 1992-09-30 | Bristol Myers Squibb Co | Method of activating cytolytic activity of lymphocytes using anti-cd28 antibody |
WO1992000092A1 (en) * | 1990-07-02 | 1992-01-09 | Bristol-Myers Squibb Company | Ligand for cd28 receptor on b cells and methods |
DE122007000078I2 (de) * | 1991-06-27 | 2011-01-13 | Bristol Myers Squibb Co | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
JPH07508711A (ja) * | 1992-04-07 | 1995-09-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Cd28経路免疫調節 |
-
1993
- 1993-04-06 JP JP5517745A patent/JPH07508711A/ja not_active Ceased
- 1993-04-06 EP EP93910570A patent/EP0637963B1/en not_active Revoked
- 1993-04-06 AT AT93910570T patent/ATE272708T1/de not_active IP Right Cessation
- 1993-04-06 CA CA 2133075 patent/CA2133075A1/en not_active Abandoned
- 1993-04-06 DE DE69333580T patent/DE69333580D1/de not_active Expired - Lifetime
- 1993-04-06 WO PCT/US1993/003155 patent/WO1993019767A1/en active IP Right Grant
- 1993-04-06 AU AU41011/93A patent/AU684461B2/en not_active Ceased
- 1993-04-06 EP EP04015607A patent/EP1488805A2/en not_active Withdrawn
-
2006
- 2006-10-18 JP JP2006284411A patent/JP2007056034A/ja not_active Withdrawn
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007056034A (ja) * | 1992-04-07 | 2007-03-08 | Regents Of The Univ Of Michigan | Cd28経路免疫調節 |
JP2007056038A (ja) * | 1994-04-29 | 2007-03-08 | Usa Government | 細胞内シグナル変換操作によるt細胞応答の調節方法 |
JP2007525225A (ja) * | 2004-02-26 | 2007-09-06 | イミュノバティブ セラピーズ, リミテッド | 細胞治療のためのt細胞を調製するための方法 |
Also Published As
Publication number | Publication date |
---|---|
WO1993019767A1 (en) | 1993-10-14 |
DE69333580D1 (de) | 2004-09-09 |
AU684461B2 (en) | 1997-12-18 |
EP0637963A1 (en) | 1995-02-15 |
EP0637963B1 (en) | 2004-08-04 |
AU4101193A (en) | 1993-11-08 |
EP1488805A2 (en) | 2004-12-22 |
EP0637963A4 (en) | 1996-07-10 |
ATE272708T1 (de) | 2004-08-15 |
JP2007056034A (ja) | 2007-03-08 |
CA2133075A1 (en) | 1993-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07508711A (ja) | Cd28経路免疫調節 | |
US20080305092A1 (en) | Methods of treating autoimmune disease via CTLA-4IG | |
US10669346B2 (en) | Monoclonal antibody and a method thereof | |
Socié et al. | Acute graft-versus-host disease: from the bench to the bedside | |
US6685941B1 (en) | Methods of treating autoimmune disease via CTLA-4Ig | |
JP2883201B2 (ja) | Cd28刺激関連免疫療法 | |
Ferrari-Lacraz et al. | An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection | |
CN109476743A (zh) | 预防或缓解毒性的早期干预方法 | |
JP2002502823A (ja) | 移植における補刺激遮断および混合キメラ現象 | |
KR20180033537A (ko) | Pd-l1 발현 조혈 줄기 세포 및 용도 | |
US20120269806A1 (en) | Methods of inducing tolerance | |
Kim et al. | Host CD25+ CD4+ Foxp3+ regulatory T cells primed by anti-CD137 mAbs inhibit graft-versus-host disease | |
Morelli et al. | Microchimerism, donor dendritic cells, and alloimmune reactivity in recipients of Flt3 ligand-mobilized hemopoietic cells: modulation by tacrolimus | |
Askenase et al. | Serotonin initiation of delayed-type hypersensitivity: mediation by a primitive Thy-1+ antigen-specific clone or by specific monoclonal IgE antibody | |
Katsumata et al. | Evaluation of the impact of conventional immunosuppressant on the establishment of murine transplantation tolerance–an experimental study | |
US11981743B2 (en) | Monoclonal antibody and a method thereof | |
Spaner et al. | Aberrant regulation of superantigen responses during T-cell reconstitution and graft-versus-host disease in immunodeficient mice | |
O'Shaughnessy | Novel molecular strategies for prevention of graft-versus-host disease by ex vivo tolerance induction | |
Cravedi | A Prospective, Randomized Study to Compare the Effect of Combination Therapy With Campath-1H on Peripheral Blood Mononuclear Cells in Kidney Transplant Recipients | |
Kitchens Jr | Costimulatory Blockade-Resistant Transplant Rejection: Mechanistic Characterization and Evaluation of Novel Immunomodulatory Regimens | |
Nanji | Tolerance induction in experimental islet transplantation | |
Organ | Rapamycin-Conditioned Dendritic Cells Are | |
Fischer et al. | This information is current as Transplant Tolerance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040315 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040510 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040512 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060620 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20061130 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070202 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070501 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070509 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20071010 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20071115 |